NCT01410695View on ClinicalTrials.gov

Masitinib in Refractory Active Rheumatoid Arthritis

PHASE2/PHASE3TerminatedINTERVENTIONAL

Enrollment

324

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG

masitinib 3 mg

DRUG

masitinib 6.0 mg

DRUG

methotrexate

DRUG

Placebo (methotrexate)

DRUG

Placebo (masitinib)

Trial Locations (1)

25301

ARTMEDI UPD s.r.o, Hostivice

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AB Science

INDUSTRY

NCT01410695 - Masitinib in Refractory Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter